返回
Duality Biotherapeutics, Inc.（9606.HK）價格
9606.HK 股價走勢圖
DUALITYBIO-B (9606.HK)
Duality Biotherapeutics, Inc.
HK$347.4
-3.92%
$-14.2
休市： Jan 20, 16:00:00 HKT
暫無資料Earnings FAQ
9606.HK 最近的每股盈餘與預期相比如何？
Duality Biotherapeutics, Inc. 9606.HK 上一季度的收入表現如何？
Duality Biotherapeutics, Inc. 的收入預期是多少？
Duality Biotherapeutics, Inc. 的盈利品質評分是多少？
Duality Biotherapeutics, Inc. 何時發布財報？
Duality Biotherapeutics, Inc. 的預期收益是多少？
Duality Biotherapeutics, Inc. 是否超出收益預期？
關鍵數據
前收市價
$355
開盤價
$361.6
當日範圍
$344.4 - $370.8
52週區間
$165.5 - $563.5
交易量
645.3K
平均成交量
1.0M
每股盈餘 (TTM)
-35.81
股息收益率
--
市值
$30.5B
什麼是 DUALITYBIO-B？
Duality Biotherapeutics, Inc. operates as a clinical stage company. The company is headquartered in Shanghai, Shanghai and currently employs 191 full-time employees. The company went IPO on 2025-04-15. The firm is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The firm's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The firm's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The firm principally conducts its businesses in domestic and overseas markets.